MA30921B1 - Formes cristallines de l'aliskiren (hemifumarate) - Google Patents
Formes cristallines de l'aliskiren (hemifumarate)Info
- Publication number
- MA30921B1 MA30921B1 MA31922A MA31922A MA30921B1 MA 30921 B1 MA30921 B1 MA 30921B1 MA 31922 A MA31922 A MA 31922A MA 31922 A MA31922 A MA 31922A MA 30921 B1 MA30921 B1 MA 30921B1
- Authority
- MA
- Morocco
- Prior art keywords
- crystalline forms
- hemifumarate
- aliskiren
- pharmaceutical preparations
- pharmaceutical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
CETTE INVENTION CONCERNE LES FORMES CRISTALLINES DE L'ALISKIREN (HÉMIFUMARATE) ET DIVERS MODES DE RÉALISATION QUI SONT ASSOCIÉS, PAR EXEMPLE LES PRÉPARATIONS PHARMACEUTIQUES, LES PROCESSUS DE FABRICATION DES FORMES CRISTALLINES, LES UTILISATIONS PHARMACEUTIQUES, ETC. LES FORMES CRISTALLINES ONT DES PROPRIÉTÉS PARTICULIÈREMENT AVANTAGEUSES, ELLES SONT NOTAMMENT UTILES DANS LA FABRICATION DES PRÉPARATIONS PHARMACEUTIQUES DESTINÉES À RÉDUIRE LA PRESSION ARTÉRIELLE.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06123642 | 2006-11-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA30921B1 true MA30921B1 (fr) | 2009-11-02 |
Family
ID=37907983
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA31922A MA30921B1 (fr) | 2006-11-07 | 2009-05-27 | Formes cristallines de l'aliskiren (hemifumarate) |
Country Status (25)
Country | Link |
---|---|
US (1) | US8119841B2 (fr) |
EP (1) | EP2079463A1 (fr) |
JP (1) | JP2010508370A (fr) |
KR (1) | KR20090083918A (fr) |
CN (1) | CN101594857B (fr) |
AR (1) | AR063560A1 (fr) |
AU (1) | AU2007323465B2 (fr) |
BR (1) | BRPI0718546A2 (fr) |
CA (1) | CA2668828A1 (fr) |
CL (1) | CL2007003194A1 (fr) |
CO (1) | CO6180428A2 (fr) |
EC (1) | ECSP099385A (fr) |
GT (1) | GT200900116A (fr) |
IL (1) | IL198470A0 (fr) |
MA (1) | MA30921B1 (fr) |
MX (1) | MX2009004885A (fr) |
MY (1) | MY148758A (fr) |
NO (1) | NO20092102L (fr) |
NZ (1) | NZ577320A (fr) |
PE (2) | PE20121179A1 (fr) |
RU (1) | RU2466982C2 (fr) |
TN (1) | TN2009000174A1 (fr) |
TW (1) | TW200827326A (fr) |
WO (1) | WO2008061622A1 (fr) |
ZA (1) | ZA200902941B (fr) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20120029083A1 (en) * | 2007-11-13 | 2012-02-02 | Teva Pharmaceutical Industries, Ltd. | Polymorphic forms of aliskiren hemifumarate and process for preparation thereof |
RU2537223C2 (ru) | 2008-01-23 | 2014-12-27 | Новартис Аг | Способ оптимизации лечения иматинибом пролиферативных заболеваний, опосредованных рецептором тирозинкиназы kit |
EP2143425A1 (fr) * | 2008-07-11 | 2010-01-13 | Ratiopharm GmbH | Tablettes d'aliskiren comprimées directement |
JO3239B1 (ar) | 2008-09-22 | 2018-03-08 | Novartis Ag | تركيبات جالينية من مركبات عضوية |
AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
DK2379497T3 (da) * | 2008-12-18 | 2013-11-25 | Novartis Ag | Hemifumaratsalt af 1-[4-cyclohexyl-3-trifluormethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl]-azetidin-3-carboxylsyre |
EP2273990A2 (fr) * | 2009-02-05 | 2011-01-19 | Teva Pharmaceutical Industries Ltd. | Formes à l'état solide de composés d'aliskirène |
EP2393489B1 (fr) | 2009-02-05 | 2014-10-08 | Krka, tovarna zdravil, d.d., Novo mesto | Processus de granulation à humidité activée |
WO2011028919A2 (fr) | 2009-09-03 | 2011-03-10 | Teva Pharmaceutical Industries Ltd. | Formes solides d'hémifumarate d'aliskirène et leurs procédés de préparation |
CN102617392B (zh) * | 2011-01-28 | 2015-04-01 | 博瑞生物医药技术(苏州)有限公司 | 一种阿利克仑半富马酸盐晶型ⅰ的制备方法 |
ITMI20111291A1 (it) * | 2011-07-11 | 2013-01-12 | Djada Pharmaceutical Sa | Aliskiren emifumarato etil acetato solvato |
ITMI20111290A1 (it) * | 2011-07-11 | 2013-01-12 | Djada Pharmaceutical Sa | Aliskiren emifumarato, forma cristallina e solido amorfo |
CN103172533B (zh) * | 2011-12-20 | 2016-05-04 | 博瑞生物医药(苏州)股份有限公司 | 一种阿利克仑半富马酸盐的新晶型及其制备方法和用途 |
JP6007096B2 (ja) * | 2011-12-28 | 2016-10-12 | エルメッド エーザイ株式会社 | 安定化カンデサルタンシレキセチル含有物の製造方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MY119161A (en) * | 1994-04-18 | 2005-04-30 | Novartis Ag | Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities |
HU228526B1 (hu) * | 2000-07-05 | 2013-03-28 | Speedel Pharma Ag | Eljárás szubsztituált oktanoil-amid-származékok elõállítására, valamint az elõállításhoz alkalmazott közbensõ termékek |
ES2369216T3 (es) * | 2002-05-17 | 2011-11-28 | Novartis Pharma Ag | Composición farmacéutica que comprende un inhibidor de renina, un bloqueador del canal de calcio y un diurético. |
PE20142101A1 (es) * | 2004-03-17 | 2014-12-27 | Novartis Ag | Composiciones farmaceuticas de aliskiren |
GB0419361D0 (en) * | 2004-08-31 | 2004-10-06 | Novartis Ag | Organic compounds |
-
2007
- 2007-11-05 CN CN2007800492907A patent/CN101594857B/zh not_active Expired - Fee Related
- 2007-11-05 EP EP07856175A patent/EP2079463A1/fr not_active Withdrawn
- 2007-11-05 AU AU2007323465A patent/AU2007323465B2/en not_active Ceased
- 2007-11-05 MY MYPI20091725A patent/MY148758A/en unknown
- 2007-11-05 PE PE2012000369A patent/PE20121179A1/es not_active Application Discontinuation
- 2007-11-05 RU RU2009121651/04A patent/RU2466982C2/ru not_active IP Right Cessation
- 2007-11-05 AR ARP070104914A patent/AR063560A1/es not_active Application Discontinuation
- 2007-11-05 US US12/312,320 patent/US8119841B2/en not_active Expired - Fee Related
- 2007-11-05 KR KR1020097011654A patent/KR20090083918A/ko not_active Application Discontinuation
- 2007-11-05 PE PE2007001518A patent/PE20081157A1/es not_active Application Discontinuation
- 2007-11-05 WO PCT/EP2007/009573 patent/WO2008061622A1/fr active Application Filing
- 2007-11-05 CA CA002668828A patent/CA2668828A1/fr not_active Abandoned
- 2007-11-05 MX MX2009004885A patent/MX2009004885A/es active IP Right Grant
- 2007-11-05 NZ NZ577320A patent/NZ577320A/en not_active IP Right Cessation
- 2007-11-05 BR BRPI0718546-4A patent/BRPI0718546A2/pt not_active IP Right Cessation
- 2007-11-05 JP JP2009535613A patent/JP2010508370A/ja active Pending
- 2007-11-06 TW TW096141915A patent/TW200827326A/zh unknown
- 2007-11-06 CL CL200703194A patent/CL2007003194A1/es unknown
-
2009
- 2009-04-29 ZA ZA200902941A patent/ZA200902941B/xx unknown
- 2009-04-30 IL IL198470A patent/IL198470A0/en unknown
- 2009-05-05 TN TNP2009000174A patent/TN2009000174A1/fr unknown
- 2009-05-06 GT GT200900116A patent/GT200900116A/es unknown
- 2009-05-27 MA MA31922A patent/MA30921B1/fr unknown
- 2009-05-28 NO NO20092102A patent/NO20092102L/no not_active Application Discontinuation
- 2009-06-04 CO CO09057907A patent/CO6180428A2/es not_active Application Discontinuation
- 2009-06-04 EC EC2009009385A patent/ECSP099385A/es unknown
Also Published As
Publication number | Publication date |
---|---|
JP2010508370A (ja) | 2010-03-18 |
CA2668828A1 (fr) | 2008-05-29 |
AR063560A1 (es) | 2009-02-04 |
US20100048716A1 (en) | 2010-02-25 |
CN101594857A (zh) | 2009-12-02 |
AU2007323465A1 (en) | 2008-05-29 |
TN2009000174A1 (en) | 2010-10-18 |
RU2009121651A (ru) | 2010-12-20 |
CN101594857B (zh) | 2012-10-31 |
CL2007003194A1 (es) | 2008-06-13 |
PE20081157A1 (es) | 2008-09-26 |
PE20121179A1 (es) | 2012-09-13 |
CO6180428A2 (es) | 2010-07-19 |
BRPI0718546A2 (pt) | 2013-11-19 |
EP2079463A1 (fr) | 2009-07-22 |
ECSP099385A (es) | 2009-07-31 |
NO20092102L (no) | 2009-07-30 |
KR20090083918A (ko) | 2009-08-04 |
MY148758A (en) | 2013-05-31 |
US8119841B2 (en) | 2012-02-21 |
RU2466982C2 (ru) | 2012-11-20 |
ZA200902941B (en) | 2010-03-31 |
WO2008061622A1 (fr) | 2008-05-29 |
GT200900116A (es) | 2011-06-07 |
MX2009004885A (es) | 2009-05-19 |
IL198470A0 (en) | 2010-02-17 |
TW200827326A (en) | 2008-07-01 |
NZ577320A (en) | 2012-01-12 |
AU2007323465B2 (en) | 2011-08-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA30921B1 (fr) | Formes cristallines de l'aliskiren (hemifumarate) | |
MA31822B1 (fr) | Compositions et methodes d'utilisation de peptides pro-ilot et leur analogues | |
BR0213358A (pt) | Uso de flibanserina | |
MA28182A1 (fr) | Analogues d'oligonucleotides de classe c presentant des proprietes immunostimulatrices accrues | |
DOP2002000429A (es) | Imidazotriazinas | |
BRPI0410503B8 (pt) | composição tópica e uso da composição | |
CL2004000192A1 (es) | Uso de compuestos derivados de 2-aminopirimidina para preparar un medicamento para la prevencion de una infeccion por vih relaciones sexuales o un contacto intimo en la pareja. | |
TNSN99252A1 (fr) | Composes nouveaux modulateurs de chimiokine ccr5 et compositions pharmaceutiques les contenant. | |
AR054139A1 (es) | Formulacion modificada y de liberacion inmediata de esferas de memantina | |
WO2002086443A8 (fr) | Procedes de diagnostic du cancer du poumon, compositions et procedes de criblage de modulateurs du cancer du poumon | |
BRPI0407662A (pt) | derivados do ácido 1-fenilalcanocarboxìlico para o tratamento de doenças neurodegenerativas | |
WO2002028999A3 (fr) | Profils d'expression genique dans les cellules granulocytaires | |
CR10099A (es) | Inmunoglobulinas dirigidas contra nogo | |
HRP20080612T3 (en) | Combination of tenofovir, ritonavir and tmc114 | |
AR058173A1 (es) | Uso de sdf-1 para el tratamiento y/o prevencion de enfermedades neurologicas | |
TNSN02015A1 (fr) | Composes nouveaux antagonistes de ppar, et compositions les contenant | |
MA31264B1 (fr) | Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison | |
BR0210650A (pt) | Tablete, e, uso do mesmo | |
WO2002062304A3 (fr) | Agents cosmetiques et/ou pharmaceutiques | |
MX2007011381A (es) | Composicion de espirulinas rica en principios activos, su proceso de obtencion y su utilizacion. | |
GT200600010A (es) | Procedimientos para la preparacion de alcoholes aminoetoxibencilicos | |
PT1368016E (pt) | Formas de dosagem parenterica que compreendem uma suspensao de sal de tramadol e sal de diclofenac | |
DK1406927T3 (da) | Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose | |
NO20051301L (no) | Proteintyrosinforfataseinhibitorer | |
BR9707083A (pt) | Formas sólidas de administração com liberação instantánea e processos para a sua produção |